

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 046658/271691

First Inventor: Meritet

Title INTERFERON-ALPHA INDUCED GENE

Express Mail Label No. EV 184330545 US

ADDRESS TO: MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Jean-Francois Meritet, 62 rue de Picpus, F-75102 Paris, France
Michel Dron, 22 avenue des Cottages, F-92340 Bourg la Reine, France
Michael Gerard Tovey, 7 rue Lagrange, F-75005 Paris, France

Assignee of this invention is Pharma Pacific Pty. Ltd.

1. ☒ The Filing Fee has been calculated as shown below:
2. ☐ Applicant claims Small Entity Status. See 37 CFR 1.27.

	No. Filed	No. Extra	Small Entity		Large Entity	
			Rate	Fee 0	Rate	Fee 1
BASIC FEE				\$ 0		\$ 770
TOTAL CLAIMS:	25 - 20 =	5	X 9 =	\$ 0	x 18 =	\$ 90
INDEP CLAIMS:	5 - 3 =	2	X 43 =	\$ 0	x 86 =	\$ 172
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+145 =	\$	+290 =	\$
*If the difference in Column 1 is less than zero, enter "0" in Column 2.			TOTAL	\$	TOTAL	\$ 1,032

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Acct. No. 16-0605.

- a. ☒ Fees required under 37 CFR 1.16 (National filing fees).
b. ☒ Fees required under 37 CFR 1.17 (National application processing fees) including any extension of time fees under 37 CFR § 1.136(a) that are required for consideration of papers filed during prosecution.
- ☒ A check in the amount of \$ 1,032.00 for the filing fee is enclosed.
- ☐ The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.
3. ☒ Specification; Total Pages 27
4. ☐ ___ Sheets of Drawing(s) (35 USC 113)
5. ☐ Declaration and Power of Attorney; [Total Pages ___]
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76
7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy (CRF)
 - b. ☐ Request for Transfer of Computer Readable Form of Sequence Listing under 37 CFR § 1.821(e) and MPEP 2422.05 (must be compliant with new rules)
 - c. ☒ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ Paper (5 Pages)
 - d. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS


- 9. ☐ Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)
- 10. ☐ 37 CFR 3.73(b) Statement (*when there is an assignee*); ☐ Power of Attorney
- 11. ☐ English Translation Document (*if applicable*)
- 12. ☒ Information Disclosure Statement (IDS)/PTO-1449; 1 Copies of IDS Citations
- 13. ☐ Preliminary Amendment
- 14. ☒ Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)
- 15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
☐ Foreign Priority is claimed as _____ Application No. _____, filed _____
- 16. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i).
Applicant must attach form PTO/SB35 or its equivalent.
- 17. ☐ Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.
- 18. **If a CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:
 - ☒ U.S. Continuation ☐ Divisional ☐ Continuation in Part (CIP)

of prior PCT Application No: PCT/GB02/02403; Filed May 22, 2002, which claims priority to United Kingdom Application No. 0112453.6, filed May 22, 2001.

Prior Application Information: Examiner: Unknown Group/Art Unit: Unknown

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. **CORRESPONDENCE ADDRESS** CUSTOMER NUMBER 00826

Signature: 
Attorney of Record: W. Murray Spruill
Attorney Registration No. 32,943

Alston & Bird LLP

Bank of America Plaza

101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000

Tel Raleigh Office (919) 862-2200


Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EV 184330545 US

Date of Deposit November 20, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Polly P. Burton

RTA01/2146234v1